Open AccessPharmacological and Clinical Studies of Ephedrine and Other Thermogenic Agonists
Author(s) -
Astrup Arne,
Breum Leif,
Toubro Søren
Publication year - 1995
Publication title -
obesity research
Language(s) - English
Resource type - Journals
eISSN - 1550-8528
pISSN - 1071-7323
DOI - 10.1002/j.1550-8528.1995.tb00224.x
Subject(s) - ephedrine , weight loss , medicine , placebo , caffeine , dexfenfluramine , adverse effect , endocrinology , appetite , cholesterol , pharmacology , obesity , fenfluramine , receptor , alternative medicine , pathology , serotonin
When given as a supplement to an energy restricted diet the sympathomimetic agent ephedrine, in combination with methylxanthines such as caffeine, improves fat loss by dual actions: a central suppression of appetite and peripheral stimulation of energy expenditure covered by fat oxidation. Mean weight loss was found to be 16.6 kg after 6 months when E+C was given as an adjuvant to an efficient hypoenergetic diet, which was 3.4 kg higher than in the placebo group. An additional 24 weeks treatment with E+C prevented relapse. In the first weeks of treatment E+C offset the hypotensive effect of energy restriction and weight loss, but the effect was transient, and after 8 weeks blood pressures were indistinguishable from those of the placebo group. E+C has no adverse effect on glucose and lipid metabolism, but has been shown to prevent the decline in HDL‐cholesterol caused by weight loss. In a comparative trial the weight loss produced by E+C was similar to that of dexfenfluramine. More research on sympathomimetics and methylxanthines should be carried out to identify combinations with improved efficiency and safety. Moreover, more long‐term trials and studies in males are required.